Janeen Noel Doyle serves as Chief Corp. & Bus. Dev. Ofcr at Janux Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Janeen Noel Doyle has executed 2 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Jan 2, 2026 involved receiving (via award) 126,000 shares valued at $0.
Janeen Noel Doyle currently holds 126,000 shares of Janux Therapeutics, Inc. (JANX), valued at approximately $0. This represents their equity stake as Chief Corp. & Bus. Dev. Ofcr.
Based on SEC Form 4 filings, Janeen Noel Doyle has been a net neutral trader of JANX stock. They have purchased $0 and sold $0 worth of shares.
Janeen Noel Doyle's most recent insider trade was on Jan 2, 2026, when they sold 126,000 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |